

1 **Alterations in the gut microbiome and metabolisms in pregnancies with**
2 **fetal growth restriction**

3 **Running title: Gut dysbiosis and metabolic disorders in FGR**

4
5 Zixin Tao^{1#}, Yun Chen^{1#}, Fang He², Jiawei Tang³, Limei Zhan⁴, Haoyue Hu¹, Ziling Ding¹, Shenghang
6 Ruan⁵, Yutao Chen³, Beier Chen³, Yan Wang¹, Xiaoling Guo⁴, Liwei Xie^{6*}, Mei Zhong^{1*}, Qitao Huang^{7*}

7
8 ¹Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou,
9 Guangdong, China

10 ²Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical
11 University, Guangzhou, Guangdong, China

12 ³The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China

13 ⁴Foshan Women and Children Hospital Affiliated to Southern Medical University, Foshan, Guangdong,
14 China

15 ⁵The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China

16 ⁶State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key
17 Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied
18 Microbiology, Institute of Microbiology, Guangdong Academy of Sciences, Guangzhou, Guangdong,
19 China

20 ⁷Department of Obstetrics and Gynecology, The First People's Hospital of Foshan, Foshan, Guangdong,
21 China

22
23 ***Correspondence:**

24 Professor Qitao Huang, Department of Obstetrics and Gynecology, The First People's Hospital of Foshan,
25 Foshan, Guangdong, China, 528000; 15920454515@163.com

26 Professor Mei Zhong, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical
27 University, Guangzhou, Guangdong, China, 510515; zhongmei@smu.edu.cn


28 Professor Liwei Xie, State Key Laboratory of Applied Microbiology Southern China, Guangdong
29 Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open
30 Laboratory of Applied Microbiology, Institute of Microbiology, Guangdong Academy of Sciences,
31 Guangzhou, Guangdong, China, 510070; xielw@gdim.cn

32 [#] These authors contributed equally to this work.

33 **Supplementary materials**34 **Supplementary Table 1**


	NP Group (n=31)	FGR Group (n=19)	<i>P</i>
Maternal features			
Age (y)	30.10±4.99	28.60±3.53	0.3322
Gestational Age (w)	39.80±1.18	37.20±1.77	<0.001
BMI (kg/m ²)	26.80±3.00	26.30±3.97	0.6154
SBP (mmHg)	117 (112-124)	124 (120-138)	0.0024
DBP (mmHg)	68.90±7.97	77.42±8.25	0.0009
PLT (×10 ⁹ /L)	229.6±59.76	250.8±54.14	0.2025
ALT (U/L)	10.27±2.97	11.87±4.98	0.2157
AST (U/L)	14.9 (12.8-17.8)	17.5 (13.2-21.8)	0.1647
ALP (U/L)	158 (131-181)	139 (117-179)	0.4662
ALB (g/L)	36.36±2.02	35.23±3.83	0.2462
TBA (μmol/L)	3.3 (2.4-5.8)	3.1 (2.6-4.6)	0.6807
TBil (μmol/L)	8.0 (7.0-9.7)	6.6 (5.5-8.2)	0.0031
DBil (μmol/L)	1.4 (1.1-1.9)	1.1 (0.8-1.5)	0.0227
Cr (μmol/L)	45.0 (42.0-49.0)	51.0 (40.0-56.0)	0.3182
Fetal features			
NW (g)	3310±301.6	2151±239.2	<0.0001
BPD (mm)	92.0 (86.0-95.0)	83.0 (75.0-87.0)	<0.0001
HC (mm)	328 (317-334)	296 (274-311)	<0.0001
AC (mm)	334 (325-345)	286 (269-303)	<0.0001
FL (mm)	72 (69-73)	63 (58-67)	<0.0001
AFV (mm)	48.8±11.6	36.7±9.0	0.0001

35 Data was assessed for normality using the Shapiro-Wilk normality test, and was presented as mean ± SD
36 or median (interquartile range). For normally distributed data, Student's *t*-test with Welch's correction
37 was performed between two groups. For non-normal distributed data, Mann-Whitney U test was
38 performed between two groups. BMI, body mass index; G, gravidity; P, parity; SBP, systolic blood
39 pressure; DBP, diastolic blood pressure; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate
40 aminotransferase; ALP, alkaline phosphatase; ALB, albumin; TBil, total bilirubin; DBil, direct bilirubin;
41 Cr, creatinine; NW, neonatal weight; BPD, biparietal diameter; HC, head circumference; AC, abdominal
42 circumference; FL, femur length; AFV, amniotic fluid volume.





43

44 **Supplementary Figure 1 (A)** Correlation heatmap of maternal gut microbiota and maternal
 45 clinical manifestations. Data was processed by Spearman's correlation test. **(B)** KEGG
 46 pathways predicted by PICRUSt analysis. (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. NP, $n = 35$;
 47 FGR, $n = 35$)



48

49 **Supplementary Figure 2 (A)** The top 25 abundant metabolites. **(B)** Correlation heatmap of
 50 maternal gut metabolites and maternal clinical manifestations. Data was processed by
 51 Spearman's correlation test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. NP, $n = 35$; FGR, $n = 35$.




52

53 **Supplementary Figure 3 (A)** The top 25 abundant metabolites. **(B)** Correlation heatmap of

54 maternal serum metabolites and maternal clinical manifestations. Data was processed by

55 Spearman's correlation test. * $P < 0.05$, ** $P < 0.01$. NP, $n = 31$; FGR, $n = 19$.



56

57 **Supplementary Figure 4** The expression of glucose transporters (*Glut1* and *Glut3*), amino
 58 acid transporters (*Slc38a1* and *Slc38a2*) and fatty acid transporters (*Cd36* and *Fabp3*) at the
 59 mRNA level in the placenta, normalized to *18S*. Data was presented as mean \pm SEM. One-
 60 way ANOVA test was conducted followed by Bonferroni test. * $P < 0.05$, ns, not significant. n
 61 = 6 /group.